HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 78.5%

Neg 0% Neu 0% Pos 78.5%

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.